Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;19(10):1498-501.
doi: 10.1016/j.bbmt.2013.07.020. Epub 2013 Jul 30.

Prevalence of hematopoietic cell transplant survivors in the United States

Navneet S Majhail  1 , Li Tao, Christopher Bredeson, Stella Davies, Jason Dehn, James L Gajewski, Theresa Hahn, Ann Jakubowski, Steven Joffe, Hillard M Lazarus, Susan K Parsons, Kim Robien, Stephanie J Lee, Karen M Kuntz
Affiliations

Prevalence of hematopoietic cell transplant survivors in the United States

Navneet S Majhail et al. Biol Blood Marrow Transplant. 2013 Oct.

Abstract

Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of transplant survivors. To adequately support their healthcare needs, there is a need to know the prevalence of HCT survivors. We used data on 170,628 recipients of autologous and allogeneic HCT reported to the Center for International Blood and Marrow Transplant Research from 1968 to 2009 to estimate the current and future number of HCT survivors in the United States. Stacked cohort simulation models were used to estimate the number of HCT survivors in the United States in 2009 and to make projections for HCT survivors by the year 2030. There were 108,900 (range, 100,500 to 115,200) HCT survivors in the United States in 2009. This included 67,000 autologous HCT and 41,900 allogeneic HCT survivors. The number of HCT survivors is estimated to increase by 2.5 times by the year 2020 (242,000 survivors) and 5 times by the year 2030 (502,000 survivors). By 2030, the age at transplant will be < 18 years for 14% of all survivors (n = 64,000), 18 to 59 years for 61% survivors (n = 276,000), and 60 years and older for 25% of survivors (n = 113,000). In coming decades, a large number of individuals will be HCT survivors. Transplant center providers, hematologists, oncologists, primary care physicians, and other specialty providers will need to be familiar with the unique and complex health issues faced by this population.

Keywords: Allogeneic; Autologous; Hematopoietic cell transplantation; Prevalence; Survivors.

PubMed Disclaimer

Conflict of interest statement

Authorship and Conflict of Interest Statement

None of the authors has any relevant financial conflicts of interest to disclose. Navneet Majhail had full access to all of the data in the study and had final responsibility for the integrity of the data, the accuracy of the data analysis, and the responsibility for the decision to submit for publication. Authors designed research (all authors), collected data (NM), performed statistical analysis (LT, KK), interpreted data (all authors), drafted the manuscript (NM, LT), and critically revised the manuscript (all authors). All authors have reviewed and approved the final version of the manuscript.

Figures

Figure 1
Figure 1
Projected number of hematopoietic cell transplant survivors in the US by year 2030
Figure 1
Figure 1
Projected number of hematopoietic cell transplant survivors in the US by year 2030
Figure 2
Figure 2
Sensitivity analyses showing how any future changes in the rate of transplant activity would affect the projected estimates for survivors in the US by year 2030
See this image and copyright information in PMC

References

    1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975–2007. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010 (accessed 01/01/2013)
    1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2011 Available at: http://www.cibmtr.org.
    1. Horan JT, Logan BR, Agovi-Johnson MA, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29(7):805–813. doi: 10.1200/JCO.2010.32.5001. Prepublished on 2011/01/12 as. - DOI - PMC - PubMed
    1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–2101. doi: 10.1056/NEJMoa1004383. Prepublished on 2010/11/26 as. - DOI - PMC - PubMed
    1. Hahn T, McCarthy P, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased utilization, older age of recipients and use of unrelated donors. Journal of Clinical Oncology. 2013 In press. - PMC - PubMed

Publication types

LinkOut - more resources